Enhanced response rate to pegylated liposomal doxorubicin in high grade serous ovarian carcinomas harbouring BRCA1 and BRCA2 aberrations. [electronic resource]
Producer: 20180814Description: 16 p. digitalISSN:- 1471-2407
- Adult
- Aged
- Aged, 80 and over
- Antibiotics, Antineoplastic -- therapeutic use
- BRCA1 Protein -- genetics
- BRCA2 Protein -- genetics
- Biomarkers, Tumor -- genetics
- Cystadenocarcinoma, Serous -- drug therapy
- Doxorubicin -- analogs & derivatives
- Female
- Follow-Up Studies
- Genetic Predisposition to Disease
- Humans
- Middle Aged
- Mutation
- Neoplasm Grading
- Ovarian Neoplasms -- drug therapy
- Polyethylene Glycols -- therapeutic use
- Polymorphism, Single Nucleotide
- Retrospective Studies
- Survival Rate
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.